Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05218343 · ClinicalTrials.gov registry record · NA
An Intuitive, Non-intrusive, Approach to Reduce Patient Harm From Inappropriate Dosing of High-risk Drugs in Older Adult Patients Across an Urban Safety Net Hospital System
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 8,640
- Enrollment target
NCT05218343: Completed NA study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT05218343 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 8,640 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (516% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05218343, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 8,640 participants
- Enrollment target
Study Summary
This study will assess whether a modification in the default dose and frequency (the first option a provider sees) during electronic prescribing of a high-risk drug can impact prescribing behavior and subsequent changes in average dose for the targeted high-risk drug, when prescribed to a hospitalized patient aged ≥65 years. In this cluster randomized crossover (CRXO) trial we will randomize a non-intrusive "nudge" intervention, which involves modifying the default dose for high-risk drugs when prescribed electronically to hospitalized patients aged ≥65 years. The CRXO trial involves 10 sites in an urban health system: five sites will start the trial under the intervention/control during a first time period (T1) after which they switch intervention/control status (T2). The primary outcome is prescription rate of a lower default dose (i.e. the geriatric standard) for 8 high-risk drugs. This study will inform the effectiveness of EHR-based "nudge" interventions to reduce inappropriate prescribing of high-risk drugs for elderly patients. Analyses ongoing, expected to finalize spring 2023
Primary Outcome
Rate at which the modified default dose (geriatric standard) and frequency for eight high-risk drugs are prescribed.
Interventions
- BEHAVIORAL EHR-based "nudge" interventions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,640 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2022-08-02 |
| Phase | NA |
What the finished NCT05218343 record still lists
NCT05218343 is an interventional study that assigns participants to a tested intervention. Its 8,640 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (516% higher).
The record links to 0 conditions, and to 1 intervention - of which EHR-based "nudge" interventions is the first listed.
NCT05218343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05218343 about?
NCT05218343 is a clinical study titled "An Intuitive, Non-intrusive, Approach to Reduce Patient Harm From Inappropriate Dosing of High-risk Drugs in Older Adult Patients Across an Urban Safety Net Hospital System". This study will assess whether a modification in the default dose and frequency (the first option a provider sees) during electronic prescribing of a high-risk drug can impact prescribing behavior and subsequent changes in average dose for the targeted high-risk drug, when prescribed to a hospitaliz...
What is the current status of trial NCT05218343?
This trial is currently completed. It is a NA study. The enrollment target is 8,640 participants. The study started on 2022-02-16. Estimated completion is 2022-08-02.
What interventions are being tested in trial NCT05218343?
The interventions under investigation include: EHR-based "nudge" interventions (BEHAVIORAL).
Who is sponsoring clinical trial NCT05218343?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05218343's enrollment target sits among peer trials
8,640 18th of 2000 higher than 1,983 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI